Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.38 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497752 | 1.00 | SLC6A2 (0.45) | SLC6A2CACNA1BUBE2MDCUN1D1NOTUM | |
| SCHEMBL4512194 | 0.96 | SLC6A2 (0.45) | SLC6A2CACNA1BUBE2MDCUN1D1NOTUM | |
| SCHEMBL4510883 | 0.96 | SLC6A2 (0.45) | SLC6A2CACNA1BUBE2MDCUN1D1NOTUM | |
| SCHEMBL4503886 | 0.95 | SLC6A2 (0.47) | SLC6A2CACNA1BUBE2MDCUN1D1HSD11B1 | |
| SCHEMBL4498997 | 0.88 | SLC6A2 (0.47) | SLC6A2CACNA1B | |
| SCHEMBL4499173 | 0.88 | SLC6A2 (0.47) | SLC6A2CACNA1B | |
| SCHEMBL3954066 | 0.85 | SLC6A2 (0.43) | SLC6A2 | |
| SCHEMBL3953301 | 0.85 | SLC6A2 (0.43) | SLC6A2 | |
| SCHEMBL3960289 | 0.85 | SLC6A2 (0.43) | SLC6A2 | |
| SCHEMBL3959825 | 0.85 | SLC6A2 (0.43) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | SLC6A2 115/4885CACNA1B 1170/4885UBE2M 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.